Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

93.63 +0.22 (+0.24%)
Delayed Quote Updated: 1:10 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 133,250
Open 94.97
Bid (Size) 93.61 (100)
Ask (Size) 93.75 (100)
Prev. Close 93.41
Today's Range 93.19 - 95.31
52wk Range 74.50 - 122.20
Shares Outstanding 66,684,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

52-Week Range 23.4% below 52-week high
93.63
74.5052W Low 122.2052W High
1 Week 5.8% below 1-week high
93.001W Low 99.441W High

Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM) traded between $74.50 and $122.20 over the past 52 weeks and last traded at $93.63, 23.4% below its 52-week high. Over the past week it ranged between $93.00 and $99.44.

Past 12 Months
-5.1%
-10.6%
-18.0%
+8.5%
-10.8%
-6.4%
1W -$5.03
1M -$11.11
3M -$20.54
6M +$7.34
YTD -$11.38
1Y -$6.38

RYTM was -6.4% over the past year, +8.5% over six months, -10.8% year to date, -5.1% in the last week.

12 Months vs Market
RYTM
-6.4%
DIA
+10.0%
SPY
+15.1%
QQQ
+24.3%
IWM
+16.2%

Over the past 12 months RYTM returned -6.4% versus DIA (Dow) +10.0%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.2%.

Volume & Liquidity 0.21× 3-mo avg
Today 133,250 3-mo avg 649.7K
1W
832.0K
1M
663.0K
3M
649.7K
6M
719.9K
YTD
757.7K
1Y
754.1K

RYTM most recently traded 133,250 shares against a 3-month average daily volume of 649.7K.

More News

Read More
News headline image
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗
Via Benzinga
News headline image
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts ↗
Via MarketBeat
News headline image
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗
Via Benzinga
Topics Earnings
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 93.63
When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 10/02/26 01:10 PM ET
What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.24B
How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.